Company Encyclopedia
View More
name
CN Mainland Pharmaceuticals
CP20007.HK
News
View More

CR Sanjiu: CHINARES PHARMA's pediatric tranquilizer and brain supplement granules have received implied approval for clinical trials

China Resources Pharmaceutical announced that its subsidiary, CR Sanjiu, has obtained implied permission for clinical trials of its pediatric calming and brain-nourishing granules. This product was jointly developed by CR Sanjiu, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen Institute for Drug Inspection and Research, and Shenzhen Traditional Chinese Medicine Manufacturing Innovation Center. It is classified as a Category 1.1 new drug in traditional Chinese medicine, intended for children with tic disorders due to spleen deficiency and phlegm accumulation, as well as wind-phlegm disturbance. The company expects that obtaining this implied permission for clinical trials will help further enrich its product line and enhance the market competitiveness of its products

AASTOCKS·
SZ
000999
-1.22%
HK
03320
-1.43%
AASTOCKS·
SZ
000999
-1.22%
HK
03320
-1.43%

Investing in Sinopharm Group (HKG:1099) three years ago would have delivered you a 34% gain

Investing in Sinopharm Group (HKG:1099) three years ago would have delivered a 34% total shareholder return, largely due to dividends, despite a modest 19% share price increase. The company's earnings per share dropped 3.7% annually, and revenue growth was only 1.1%. The CEO's pay is below the median for similar-sized companies. Analysts predict future profit estimates, and investors should consider market conditions and investment risks.

Simplywall·
HK
01099
-0.20%
Simplywall·
HK
01099
-0.20%

Fosun Pharma’s Subsidiary Gains Approval for New Drug Application

Shanghai Fosun Pharmaceutical's subsidiary, Shanghai Zhaohui Pharmaceutical, has received approval for its drug registration application for Polyethylene Glycol (3350) Electrolytes Powder from the National Medical Products Administration. This drug targets chronic constipation and represents a significant R&D investment of RMB6.21 million. The approval could strengthen Fosun Pharma's market position in China. The latest analyst rating for Fosun Pharma's stock (HK:2196) is a Buy with a target price of HK$35.30.

Tip Ranks·
HK
02196
-0.09%
SH
600196
-1.18%
Tip Ranks·
HK
02196
-0.09%
SH
600196
-1.18%

Shandong Xinhua Pharmaceutical Secures Regulatory Approval for Vonoprazan Fumarate API

Shandong Xinhua Pharmaceutical Company Limited has received regulatory approval from the National Medical Products Administration for its Vonoprazan Fumarate API. This approval is expected to expand the company's product line and enhance competitiveness. The announcement notes that the pharmaceutical sales business is subject to industry policy changes and market factors. The original content was published by Shandong Xinhua Pharmaceutical on November 17, 2025.

Reuters·
SZ
000756
-1.67%
HK
00719
-0.85%
Reuters·
SZ
000756
-1.67%
HK
00719
-0.85%

Bank of America Securities Keeps Their Buy Rating on MicroPort Scientific (MCRPF)

In a report released on November 13, from Bank of America Securities maintained a Buy rating on MicroPort Scientific, with a price target of HK$17.00. The company’s shares closed last Thursday at HK$11.48.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. MicroPort Scientific has an analyst consensus of Moderate Buy, with a price target consensus of $1.98.

Tip Ranks·
HK
00853
-2.71%
Tip Ranks·
HK
00853
-2.71%
Posts
View More